On July 6, 3SBio rose 3.94% in regular trading, trading at HK$20.08 per share, with turnover of HK$269 million. The stock extended its multi-day rally as the innovative drug payment reform catalyst continued to resonate across the biotech sector.
On the policy front, the National Healthcare Security Administration recently published the initial review results for the 2026 medical insurance directory, with 557 drugs passing basic medical insurance review and 54 drugs passing the commercial insurance innovative drug directory review. This marks the substantive advancement of the dual-directory negotiation mechanism combining basic medical insurance and commercial insurance, while new mechanisms including pre-declaration and 8-year price protection have simultaneously taken effect, further stabilizing commercial expectations for innovative drug enterprises.
At the company level, 3SBio completed three consecutive buybacks on June 22, 25, and 26, repurchasing approximately 8.52 million shares for a total of HK$135 million. Chairman Lou Jing purchased 516,000 shares on June 8, and Fullgoal Fund increased its holding by 636,500 shares on June 10, forming a combined confidence signal. Within the biotech sector, Remegen rose 4.78%, Innovent Biologics rose 4.21%, and SKB Bio rose 2.81%, reflecting broad sector beta resonance.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments